Any comments on these trial results re: Peginterfe
Post# of 155038
(Total Views: 514)
Posted On: 03/18/2022 9:09:14 AM
Any comments on these trial results re: Peginterferon Lambda?
It looks like this study (below) used people not yet hospitalized, so I'm not sure how this compares/competes with Leronlimab:
Eiger BioPharmaceuticals Inc (NASDAQ: EIGR) announced data from the Phase 3 TOGETHER study evaluating Peginterferon Lambda in non-hospitalized COVID-19 adult patients at high risk of progressing to severe illness.
Peginterferon Lambda significantly reduced the risk of COVID-19-related hospitalizations or emergency room visits by 50% (primary endpoint) and death by 60%.
The Phase 3 TOGETHER study of Lambda is the second largest study to date of a COVID-19 therapeutic.
Final analyses evaluated data from 1,936 patients, with 84% of patients receiving at least a single dose of any COVID-19 vaccine.
2.7% of patients (25 / 916) who received Lambda were hospitalized or had ER visits through Day 28, compared to 5.6% of patients who received placebo
42% risk reduction of COVID-19-related hospitalizations was observed when treated ≤7 days of symptom onset, and 60% when treated ≤3 days.
One COVID-19-related death was reported in the Lambda group, and four in the placebo group.
Eiger plans to discuss the results with FDA and submit a EUA as soon as possible.
It looks like this study (below) used people not yet hospitalized, so I'm not sure how this compares/competes with Leronlimab:
Eiger BioPharmaceuticals Inc (NASDAQ: EIGR) announced data from the Phase 3 TOGETHER study evaluating Peginterferon Lambda in non-hospitalized COVID-19 adult patients at high risk of progressing to severe illness.
Peginterferon Lambda significantly reduced the risk of COVID-19-related hospitalizations or emergency room visits by 50% (primary endpoint) and death by 60%.
The Phase 3 TOGETHER study of Lambda is the second largest study to date of a COVID-19 therapeutic.
Final analyses evaluated data from 1,936 patients, with 84% of patients receiving at least a single dose of any COVID-19 vaccine.
2.7% of patients (25 / 916) who received Lambda were hospitalized or had ER visits through Day 28, compared to 5.6% of patients who received placebo
42% risk reduction of COVID-19-related hospitalizations was observed when treated ≤7 days of symptom onset, and 60% when treated ≤3 days.
One COVID-19-related death was reported in the Lambda group, and four in the placebo group.
Eiger plans to discuss the results with FDA and submit a EUA as soon as possible.
(0)
(0)